CSIIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (28 4月 2023 @ 05:00):

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally...

Stats
本日の出来高	387 776
平均出来高	677 842
時価総額	843.96M
EPS	$0 ( 2024-02-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.83
ATR14	$0.103 (0.52%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Paulsen Erik	Sell	20 627	Restricted Stock Units
2023-04-27	Paulsen Erik	Sell	700	Common Stock
2023-04-27	Points Jeffrey S.	Sell	138 957	Common Stock
2023-04-27	Points Jeffrey S.	Sell	34 051	Common Stock
2023-04-27	Rempe Stephen J.	Sell	75 659	Common Stock

INSIDER POWER
-78.95
Last 100 transactions
Buy: 675 433 \| Sell: 1 911 221

ボリューム相関

長: 0.24 (neutral)

短: -0.52 (weak negative)

Signal:(76.086) Neutral

Cardiovascular Systems 相関

10 最も正の相関
ATCX	0.992
TA	0.978
IIN	0.972
ECHO	0.968
SPRB	0.966
IFRX	0.963
LGMK	0.962
BUR	0.956
EZFL	0.948
SHC	0.947

10 最も負の相関
MDXH	-0.959
TENX	-0.952
SMH	-0.951
BSET	-0.948
SINT	-0.944
ONCT	-0.944
CYXT	-0.944
SIRI	-0.937
VTRU	-0.934
NDRA	-0.934

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cardiovascular Systems 相関 - 通貨/商品

-0.38
( neutral )

0.42
( neutral )

0.57
( weak )

-0.16
( neutral )

0.16
( neutral )

0.36
( neutral )

Cardiovascular Systems 財務諸表

Annual	2022
収益:	$236.22M
総利益:	$172.78M (73.14 %)
EPS:	$-0.940

FY	2022
収益:	$236.22M
総利益:	$172.78M (73.14 %)
EPS:	$-0.940

FY	2021
収益:	$258.97M
総利益:	$197.84M (76.39 %)
EPS:	$-0.350

FY	2020
収益:	$236.55M
総利益:	$187.79M (79.39 %)
EPS:	$-0.790

Financial Reports:

No articles found.

Cardiovascular Systems

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.